Navigation Links
Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS

SAN FRANCISCO, CA -- July 11, 2011 -- The Gladstone Institutes will receive funds totaling $5.6 million over five years as part of the first-ever major funding initiative focusing on HIV eradication. The funds will help three principal investigators at Gladstone, an independent biomedical-research organization, to explore the molecular basis for HIV latency where the virus that causes AIDS "hides" dormant within cells waiting for an opportunity to reemerge when therapy is withdrawn.

"A critical factor to finding a cure for AIDS is to solve the problem of HIV latency," said Warner Greene, MD, PhD who leads all virology and immunology research at Gladstone. "If we can inhibit latency, then a cure for HIV-infected patients could be within our reach."

AIDS has killed more than 25 million people around the world since first being identified some 30 years ago. In the United States alone, more than one million people live with HIV/AIDS at an annual cost of $34 billion. Patients require lifelong treatment for AIDS because the HIV virus persists in a dormant and drug-insensitive form. Better understanding this latency, and developing new ways to attack it, could finally make it possible to cure HIV-infected patients.

The funding to cure this latency is part of the Martin Delaney Collaboratory a consortium among academia, government and private industry that the National Institutes of Health is funding and that Dr. Greene helped create. The National Institute of Mental Health also provided co-funding.

With these funds, Dr. Greene's laboratory will seek to identify previously unrecognized products in the cell that help maintain HIV latency ultimately working to develop inhibitors against these cellular proteins. Dr. Greene's laboratory also will analyze the action and targets of various regulatory molecules known as microRNAs that are present in latently infected CD4 T cells. Eric Verdin, MD, will study the potential role of the cell's chromatin-remodeling machines in the establishment and maintenance of HIV latency; while Melanie Ott, PhD, will examine the role of histone methylation in HIV latency and the effects of small-molecule inhibitors that block the action of various methyl transferases.

"If we can successfully eradicate latency, we might be able to avoid drug therapy altogether," said Dr. Verdin, who is a senior investigator at Gladstone.

At the same time, Dr. Greene warned, any eventual cures or functional cures can't begin to end the global AIDS epidemic unless they can be effectively used in those places where the virus is most rampant such as sub-Saharan Africa, where about two-thirds of all people afflicted with HIV/AIDS live.

"We must construct a therapy that is usable in both the developing and developed world," said Dr. Greene, who is also a professor of medicine, microbiology and immunology at the University of California, San Francisco (UCSF).

The $5.6 million that Gladstone is receiving is part of the $32 million that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded over five years to the University of North Carolina at Chapel Hill. That money will be shared among 19 investigators, including those at Gladstone and at nine U.S. universities including UCSF, with which Gladstone is affiliated.

The UNC-led consortium will be one of three groups funded by NIAID under its Martin Delaney Collaboratory initiative. The UNC-led effort will undertake more than a dozen research projects to discover how the virus can remain dormant and virtually invisible, identify drugs and treatments capable of ridding the body of persistent infection and to evaluate these new strategies in relevant animal models followed by testing of the most promising candidates in humans.

The Collaboratory also includes an important industrial partner, Merck Research Laboratories of Whitehouse Station, N.J. Merck has a track record in the development of small-molecule drugs and other therapies that target viral reservoirs. While Merck Research Laboratories will not receive federal funds for their contribution to this research, they will provide core resources to the academic investigators.


Contact: Mara Brazer
Gladstone Institutes

Related biology news :

1. Gladstone scientists identify genes involved in embryonic heart development
2. Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimers disease
3. Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
4. Gladstones Shinya Yamanaka wins Kyoto prize
5. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
6. Gladstones Shinya Yamanaka wins Lasker Award
7. Gladstone scientists identify key factors in heart cell creation
8. Gladstone scientists reveal key enzyme in fat absorption
9. Gladstone scientists reveal that fat synthesizing enzyme is key to healthy skin and hair
10. NJIT receives second part of $1M gift to chemical engineering department
11. Texas Parks Wildlife Commission member Karen Hixon to receive ESAs 2011 Regional Policy Award
Post Your Comments:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: